文献速递消化道肿瘤放疗姑息放疗与转移瘤

直肠癌保留器官治疗中接触X线近距离放疗与放化疗后的临床缓解评估:时间/剂量因素的影响

Clinical response assessment after contact X-Ray brachytherapy and chemoradiotherapy for organ preservation in rectal cancer T2-T3 M0: The time/dose factor influence.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-07-06

本研究回顾性分析61例T2-T3 M0直肠腺癌患者,比较以接触X线近距离放疗(CXB)或外照射放疗(EBRT)起始的新辅助治疗对前6个月临床缓解的影响。结果显示第14周时CXB起始组临床完全缓解率88%,EBRT起始组33%,多因素分析治疗时序是影响cCR的最显著因素(OR=7.53)。

要点

  • CXB起始治疗组第14周cCR率88%,显著高于EBRT起始组的33%。
  • 多因素分析中治疗时序是影响cCR的最显著因素(OR=7.53)。
  • 6个月时CXB起始组全部达临床完全缓解,EBRT起始组5例仍为部分缓解。

核心结论

  • 在早期T2-T3直肠癌中,以接触X线近距离放疗起始、缩短总治疗时间的策略可能比EBRT起始获得更有利的结局。

研究设计与样本

  • 2002至2017年回顾性连续队列,纳入61例T2-T3 M0直肠腺癌患者(T2 31例,T3 30例,中位年龄76岁),均以保留器官为目的。
  • 治疗方案联合CXB(80-110 Gy/3-4次)和EBRT±同步卡培他滨;肿瘤超过3.5 cm时常用EBRT起始。
  • 40例(T2 28例,T3 12例)以CXB起始,21例(T2 4例,T3 17例)以EBRT起始。

主要发现

  • 第14周(±1周)临床完全或近完全缓解率:CXB起始组88%[95%CI:74-96],EBRT起始组33%[95%CI:15-57]。
  • 多因素分析中治疗时序是影响cCR的最显著因素(OR:7.53)。
  • 6个月时CXB起始组全部患者达临床完全缓解,EBRT起始组5例仍为部分缓解。
  • 中位随访61个月,5年局部复发率10%[95%CI:6-16],T3和蕈伞型肿瘤局部复发风险更高。
  • 95%病例实现保留器官且功能良好。

关键数值与推荐

  • CXB剂量方案为80-110 Gy分3-4次。
  • 临床缓解评估在治疗开始后2周至6个月间以密切间隔进行(DRE、直肠镜±影像)。

临床怎么用

  • 对早期T2-T3 M0直肠癌,可考虑以CXB起始的新辅助治疗以缩短总治疗时间并提高早期cCR率。
  • 治疗开始后2周至6个月间应密切评估临床缓解,尤其关注第14周时间点。
  • T3和蕈伞型肿瘤局部复发风险较高,需加强随访。

局限性

  • 非随机回顾性研究,样本量61例,存在选择偏倚可能。
  • 肿瘤超过3.5 cm时常用EBRT起始,治疗分组与肿瘤大小相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A neoadjuvant treatment aimed at rectal preservation should achieve a clinical complete response. This study comparing neoadjuvant treatment initiated with Contact X-ray (CXB) or External Beam radiotherapy (EBRT) is evaluating the influence of the time/dose parameter on clinical response during the first six months. MATERIALS AND METHODS: This retrospective consecutive series included T2-3 rectal adenocarcinoma staged using digital examination (DRE), endoscopy, magnetic radiation imaging and/or endorectal ultrasound. All patients were treated with organ preservation intent. Treatment protocol combined CXB (80-110 Gy/3-4 fractions) and EBRT ± concurrent capecitabine. In tumor exceeding 3.5 cm treatment was often initiated using EBRT. Clinical response was assessed (DRE, proctoscopy ± imaging) at very close interval between 2 weeks and 6 months after treatment initiation. RESULTS: Between 2002 and 2017, 61 patients (T2: 31; T3: 30) M0 (median age: 76 years) were treated. Treatment was initiated in 40 patients (T2: 28, T3: 12) with contact X-ray and in 21 (T2: 4, T3: 17) with EBRT. Using contact X-ray or EBRT first treatment, clinical complete (or near complete) response at week 14(±1) was respectively 88% [95CI:74-96] and 33% [95CI:15-57]. In multivariate analysis the treatment chronology was the most significant factor influencing cCR (OR: 7.53). At 6 months, with contact X-ray first all patients were in clinical complete response and five with EBRT remained in partial response. With 61 months median follow-up time, the local recurrence rate was 10% [95% CI: 6-16] at 5 years. T3 and fungating tumors were at higher risk of local recurrence. Organ preservation with good function was achieved in 95% of cases. CONCLUSION: This non randomized study tends to show that in early T2-3 tumors, a strategy using upfront contact therapy, which is reducing the overall treatment time, is an option allowing a more favorable outcome than EBRT first.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Benezery K, Montagne L, Evesque L, et al. Clinical response assessment after contact X-Ray brachytherapy and chemoradiotherapy for organ preservation in rectal cancer T2-T3 M0: The time/dose factor influence. Clin Transl Radiat Oncol. 2020. PMID: 32695890. doi:10.1016/j.ctro.2020.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。